A patient with stage IV type 4 advanced gastric cancer who had a complete pathological response to short-term treatment with S-1 alone

被引:2
|
作者
Ishido, Kenji [1 ]
Koizumi, Wasaburo [1 ]
Tanabe, Satoshi [1 ]
Higuchi, Katsuhiko [1 ]
Sasaki, Tohru [1 ]
Katada, Chikatoshi [1 ]
Azuma, Mizutomo [1 ]
Salgenji, Katsunori [1 ]
Futawatari, Nobue [2 ]
Saegusa, Makoto [3 ]
机构
[1] Kitasato Univ, E Hosp, Dept Gastroenterol, Kanagawa 2288520, Japan
[2] Kitasato Univ, E Hosp, Dept Surg, Kanagawa 2288520, Japan
[3] Kitasato Univ, E Hosp, Dept Pathol, Kanagawa 2288520, Japan
关键词
chemotherapy; gastric cancer; S-1;
D O I
10.1097/CAD.0b013e32830d58a6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An 81-year-old woman presented with dysphagia. Stage IV (cT3, cN3, cH0, cM1) type 4 advanced gastric cancer was diagnosed. The left adrenal gland and the paragastric, mediastinal, and abdominal para-aortic lymph nodes were enlarged. Ascites was present The patient started to receive S-1 (100 mg/day), given orally for 4 weeks followed by 2 weeks of rest. During the first course of treatment, grade 2 anorexia, grade 2 vomiting, and grade 2 diarrhea developed. Treatment with S-1 was therefore discontinued on day 27 The tumor had shrunk and was severely deformed. There was marked narrowing of the pyloric antrum. Abdominal computed tomography revealed that ascites and enlargement of the left adrenal gland and paragastric lymph nodes had resolved. To ensure adequate oral intake and improve the patient's quality of life, a total gastrectomy with a limited (D1) lymph node dissection was performed. The primary gastric tumor, resected lymph nodes, and a peritoneal-lavage specimen were all negative for tumor. Histologically, the tumor had a complete pathological response to S-1. Two years after surgery, the patient is alive, with no evidence of metastasis or recurrence.
引用
收藏
页码:921 / 925
页数:5
相关论文
共 50 条
  • [31] Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer
    Seiji Satoh
    Hiroshi Okabe
    Satoshi Teramukai
    Suguru Hasegawa
    Nobuhiro Ozaki
    Shugo Ueda
    Ayumi Tsuji
    Satomi Sakabayashi
    Masanori Fukushima
    Yoshiharu Sakai
    Gastric Cancer, 2012, 15 : 61 - 69
  • [32] Pathological Complete Response to Nivolumab, S1, Oxaliplatin, and Radiation in a Patient with Gastric Cancer: a Case Report
    Kazuhiro Toyota
    Yasushi Hashimoto
    Yoshihiro Sakashita
    Yujiro Yokoyama
    Yoshiaki Murakami
    Shinya Takahashi
    Katsunari Miyamoto
    Journal of Gastrointestinal Cancer, 2023, 54 : 1000 - 1002
  • [33] Pathological Complete Response to Nivolumab, S1, Oxaliplatin, and Radiation in a Patient with Gastric Cancer: a Case Report
    Toyota, Kazuhiro
    Hashimoto, Yasushi
    Sakashita, Yoshihiro
    Yokoyama, Yujiro
    Murakami, Yoshiaki
    Takahashi, Shinya
    Miyamoto, Katsunari
    JOURNAL OF GASTROINTESTINAL CANCER, 2023, 54 (03) : 1000 - 1002
  • [34] Short-term curative effect of S-1 plus oxaliplatin as perioperative chemo-therapy for locally advanced gastric cancer: a prospective comparison study
    Zhao, Qun
    Li, Yong
    Huang, Jian
    Fan, Liqia
    Tan, Bibo
    Tian, Yuan
    Yang, Peigang
    Jiao, Zhikai
    Zhao, Xuefeng
    Zhang, Zhidong
    Wang, Dong
    Liu, Yu
    PHARMAZIE, 2017, 72 (04): : 236 - 240
  • [35] Pathological complete response in a patient with locally advanced pancreatic adenocarcinoma treated with neoadjuvant gemcitabine and S-1: a case report and literature review
    Hua, Surong
    Gao, Junyi
    Xu, Qiang
    Hong, Xiafei
    Wu, Wenming
    GLAND SURGERY, 2022, 11 (02) : 494 - 503
  • [36] S-1 combined with cisplatin versus cisplatin alone for the treatment of advanced gastric cancer: a pilot randomized-controlled trial
    Wu, Di
    Li, Xin
    Tong, Jinxue
    Sun, Lingyu
    Zheng, Hongqun
    Gao, Changlu
    Yang, Dongdong
    Liu, Dongzhe
    Zhang, Qifan
    ANTI-CANCER DRUGS, 2015, 26 (07) : 774 - 778
  • [37] Pathological complete response induced by the combination therapy of S-1 and 24-h infusion of cisplatin in two cases initially diagnosed as inoperable advanced gastric cancer
    Ina, Kenji
    Kataoka, Takae
    Takeuchi, Yuuki
    Fukuoka, Tomoki
    Miwa, Takaya
    Nishio, Tomoko
    Furuta, Ryuichi
    Masaki, Ayako
    Mori, Fumiko
    Kayukawa, Satoshi
    Nagao, Seiji
    Ando, Takafumi
    Goto, Hidemi
    ONCOLOGY REPORTS, 2008, 20 (02) : 259 - 264
  • [38] REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer
    Sekikawa, A.
    Fukui, H.
    Zhang, X.
    Maruo, T.
    Tsumura, T.
    Okabe, Y.
    Wakasa, T.
    Osaki, Y.
    Chiba, T.
    Tomita, T.
    Oshima, T.
    Watari, J.
    Miwa, H.
    BRITISH JOURNAL OF CANCER, 2013, 108 (02) : 395 - 401
  • [39] REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer
    A Sekikawa
    H Fukui
    X Zhang
    T Maruo
    T Tsumura
    Y Okabe
    T Wakasa
    Y Osaki
    T Chiba
    T Tomita
    T Oshima
    J Watari
    H Miwa
    British Journal of Cancer, 2013, 108 : 395 - 401
  • [40] Meta-enrichment analysis to identify a higher response patient population to S-1/cisplatin for advanced gastric cancer
    Takeuchi, M.
    Takeuchi, M.
    van Laarhoven, H. W. M.
    Fang, X.
    Pfeiffer, P.
    Ajani, J. A.
    ANNALS OF ONCOLOGY, 2018, 29 : 655 - 655